The company’s lead product candidate, AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis. AB002 is currently in the phase 2 clinical trial stage and has received FDA Fast Track designation. It is being developed for heparin intolerant end-stage renal disease patients on chronic hemodialysis, as well as for heart attack, ischemic stroke, pulmonary embolism, and other acute blood clotting disorders.

RIGHTS

AB023 (Gruticibart) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.

RIGHTS

AB054 is a recombinant antibody that targets factor XII (FXII) and acts as a potent inhibitor of FXII-dependent thrombin generation and inflammatory kallikrein production. Based on mechanistic rationale and compelling in vivo data, we propose that targeting FXII with AB054 may be a safe and effective antithrombotic/anti-inflammatory strategy. AB054 is in the IND-enabling stage of development for multiple indications.

RIGHTS

AB062 is a first-in-class antisense oligonucleotide that reduces synthesis of thrombopoietin. AB062 is in early pre-clinical development for multiple indications, including cardiovascular and neoplastic diseases.

RIGHTS

Osocimab is a fully human monoclonal antibody that targets factor XIa. Osocimab is being developed by Bayer as part of a development and commercialization agreement with Aronora.

RIGHTS